PDE10A and neurodegenerative disease: Given its selective expression in striatum (Seeger et al, 2003; Coskran et al, 2006; Xie et al, 2006; Lakics et al, 2010; Jager et al, 2012), where it is the major cAMP‐degrading enzyme (Russwurm et al, 2015) involved in regulating neuronal activity (Dedeurwaerdere et al, 2011; Piccart et al, 2014; Padovan‐Neto et al, 2015; Wilson et al, 2015), plasticity (Yagishita et al, 2014), and gene expression (Siuciak et al, 2006; Kleiman et al, 2011), PDE10A has emerged as a prime candidate for the treatment of various psychiatric and neurodegenerative diseases (Wilson & Brandon, 2015).